Schering-Plough Resolves Lawsuit Alleging Cover-Up of GMP Problems

Schering-Plough will pay $165 million to resolve a class action lawsuit alleging it failed to disclose manufacturing issues that resulted in delayed FDA approval for its allergy drug Clarinex. The plaintiffs claim Schering-Plough violated federal securities laws by failing to disclose “the alleged depth and severity” of manufacturing issues affecting plants in New Jersey and Puerto Rico, according to a recent company filing with the SEC.
Drug Industry Daily